📣 VC round data is live. Check it out!

DSM-Firmenich Valuation Multiples

Discover revenue and EBITDA valuation multiples for DSM-Firmenich and similar public comparables like Rongsheng Petro Chemical, CF Industries, Ems-Chemie, International Flavors & Fragrances and more.

DSM-Firmenich Overview

About DSM-Firmenich

DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.


Founded

2022

HQ

Switzerland

Employees

27.0K

Sectors

Financials (LTM)

Revenue: $13B
EBITDA: $2B

EV

$23B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DSM-Firmenich Financials

DSM-Firmenich reported last 12-month revenue of $13B and EBITDA of $2B.

In the same LTM period, DSM-Firmenich generated $7B in gross profit, $2B in EBITDA, and $767M in net income.

Revenue (LTM)


DSM-Firmenich P&L

In the most recent fiscal year, DSM-Firmenich reported revenue of $15B and EBITDA of $4B.

DSM-Firmenich is profitable as of last fiscal year, with gross margin of 28%, EBITDA margin of 30%, and net margin of 6%.

See analyst estimates for DSM-Firmenich
LTMLast FY202320242025202620272028
Revenue$13B$15B$12B$15B$11B
Gross Profit$7B$4B$3B$5B$4B
Gross Margin51%28%25%33%39%
EBITDA$2B$4B$962M$2B$4B
EBITDA Margin19%30%8%14%43%
EBIT Margin10%11%(5%)4%7%
Net Profit$767M$825M$2B$291M($1B)
Net Margin6%6%20%2%(12%)
Net Debt—$4B———

Financial data powered by Morningstar, Inc.

DSM-Firmenich Stock Performance

DSM-Firmenich has current market cap of $19B, and enterprise value of $23B.

Market Cap Evolution


DSM-Firmenich's stock price is $76.72.

DSM-Firmenich share price increased by 3.3% in the last 30 days, and decreased by 32.2% in the last year.

DSM-Firmenich has an EPS (earnings per share) of $3.31.

See more trading valuation data for DSM-Firmenich
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$23B$19B-3.0%3.3%7.5%-32.2%$3.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DSM-Firmenich Valuation Multiples

DSM-Firmenich trades at 1.7x EV/Revenue multiple, and 9.3x EV/EBITDA.

See NTM and 2027E valuation multiples for DSM-Firmenich

EV / Revenue (LTM)


DSM-Firmenich Financial Valuation Multiples

As of May 18, 2026, DSM-Firmenich has market cap of $19B and EV of $23B.

DSM-Firmenich has a P/E ratio of 24.9x.

LTMLast FY202320242025202620272028
EV/Revenue1.7x1.5x1.9x1.5x2.2x
EV/EBITDA9.3x5.2x24.0x11.1x5.2x
EV/EBIT17.2x14.7x(39.1x)36.8x31.4x
EV/Gross Profit3.4x5.6x7.6x4.7x5.6x
P/E24.9x23.2x7.7x65.8x(15.2x)
EV/FCF26.5x30.5x35.5x19.7x30.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DSM-Firmenich Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DSM-Firmenich Margins & Growth Rates

DSM-Firmenich decreased revenue by 28% and EBITDA by 54% in the last fiscal year.

In the most recent fiscal year, DSM-Firmenich reported gross margin of 28%, EBITDA margin of 30%, and net margin of 6%.

See estimated margins and future growth rates for DSM-Firmenich

DSM-Firmenich Margins

Last FY202420252026202720282029
Gross Margin28%33%39%39%
EBITDA Margin30%14%43%19%
EBIT Margin11%4%7%9%
Net Margin6%2%(12%)6%
FCF Margin5%8%7%10%

DSM-Firmenich Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(28%)20%(29%)2%
Gross Profit Growth2%63%(17%)2%
EBITDA Growth(54%)116%115%(54%)
EBIT Growth(38%)(206%)17%32%
Net Profit Growth(19%)(88%)(532%)(153%)
FCF Growth41%80%(35%)41%

Data powered by FactSet, Inc. and Morningstar, Inc.

DSM-Firmenich Operational KPIs

DSM-Firmenich's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

DSM-Firmenich's Rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DSM-Firmenich's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DSM-Firmenich
LTMLast FY202320242025202620272028
Rule of 400%21%———
Bessemer Rule of X(27%)23%———
Revenue per Employee—$0.6M———
Opex per Employee—$0.1M———
S&M Expenses to Revenue—10%14%14%14%
G&A Expenses to Revenue—7%10%8%10%
R&D Expenses to Revenue5%6%6%7%8%
Opex to Revenue—23%29%29%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

DSM-Firmenich Competitors

DSM-Firmenich competitors include Rongsheng Petro Chemical, CF Industries, Ems-Chemie, International Flavors & Fragrances, LG Chem, SABIC Agri-Nutrient, DuPont, Borouge, Industries Qatar and Chandra Asri Group.

Most DSM-Firmenich public comparables operate across Chemicals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Rongsheng Petro Chemical1.1x1.0x12.4x9.6x
CF Industries2.9x2.8x6.3x6.1x
Ems-Chemie7.5x7.5x23.6x23.5x
International Flavors & Fragrances2.3x2.3x11.8x11.7x
LG Chem1.1x1.0x7.9x7.4x
SABIC Agri-Nutrient4.3x4.3x9.7x10.5x
DuPont3.3x3.3x13.9x13.5x
Borouge3.9x3.8x10.5x10.5x

This data is available for Pro users. Sign up to see all DSM-Firmenich competitors and their valuation data.

Start Free Trial

DSM-Firmenich M&A Activity

DSM-Firmenich has acquired 2 companies to date.

Last acquisition by DSM-Firmenich was on April 19th 2023. DSM-Firmenich acquired Adare Biome for $297M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by DSM-Firmenich

Adare Biome
DSM
Description
Adare Biome is a biotechnology firm based in Barcelona, Spain, specializing in microbiome-based postbiotics for human and animal health applications. The company develops targeted microbial solutions to modulate gut health, immune responses, and metabolic functions using proprietary strains isolated from natural sources. Adare Biome partners with pharmaceutical and nutraceutical companies to deliver clinical-stage products addressing conditions like inflammatory bowel disease and obesity. Founded in 2019 as a spin-off from Adare Pharmaceuticals, it leverages advanced fermentation and encapsulation technologies for stable, scalable postbiotic formulations.
DSM is a Dutch multinational specializing in nutrition, health, and sustainable materials, generating €12 billion in annual sales post its 2023 merger with Firmenich to form dsm-firmenich. Headquartered in Kaiseraugst, Switzerland, it employs 30,000 people across 60 countries, supplying omega-3s for food fortification, enzymes for animal feed, and engineering plastics for automotive components like airbag housings.
HQ CountryFranceNetherlands
HQ City
Paris
Heerlen
Deal Date19 Apr 20233 Apr 2023
Valuation$297Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich acquisitions and their M&A valuation multiples.

Start Free Trial

DSM-Firmenich Investment Activity

DSM-Firmenich has invested in 1 company to date.

Latest investment by DSM-Firmenich was on March 13th 2024. DSM-Firmenich invested in Cynomys in their $2M Seed round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by DSM-Firmenich

Cynomys
Description
Cynomys is an Italian IoT company that patented sensors for monitoring over 30 parameters in livestock farms including welfare, emissions, and resource use. Launched in 2018 from Modena, the cloud-connected devices track temperature, humidity, feed intake, and ammonia levels for cattle, swine, and poultry operations. Cynomys serves feed producers and large farms in Italy, Spain, France, Netherlands, and Mexico, optimizing productivity and sustainability via remote dashboards.
HQ CountryItaly
HQ City
Ronco Scrivia
Deal Date13 Mar 2024
RoundSeed
Raised$2M
InvestorsDSM-Firmenich; Farming Future; Levante Capital; PLUS9; SVG Ventures
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DSM-Firmenich investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DSM-Firmenich

When was DSM-Firmenich founded?DSM-Firmenich was founded in 2022.
Where is DSM-Firmenich headquartered?DSM-Firmenich is headquartered in Switzerland.
How many employees does DSM-Firmenich have?As of today, DSM-Firmenich has over 27K employees.
Is DSM-Firmenich publicly listed?Yes, DSM-Firmenich is a public company listed on Euronext Amsterdam.
What is the stock symbol of DSM-Firmenich?DSM-Firmenich trades under DSFIR ticker.
When did DSM-Firmenich go public?DSM-Firmenich went public in 2023.
Who are competitors of DSM-Firmenich?DSM-Firmenich main competitors include Rongsheng Petro Chemical, CF Industries, Ems-Chemie, International Flavors & Fragrances, LG Chem, SABIC Agri-Nutrient, DuPont, Borouge, Industries Qatar, Chandra Asri Group.
What is the current market cap of DSM-Firmenich?DSM-Firmenich's current market cap is $19B.
What is the current revenue of DSM-Firmenich?DSM-Firmenich's last 12 months revenue is $13B.
What is the current revenue growth of DSM-Firmenich?DSM-Firmenich revenue growth (NTM/LTM) is (18%).
What is the current EV/Revenue multiple of DSM-Firmenich?Current revenue multiple of DSM-Firmenich is 1.7x.
Is DSM-Firmenich profitable?Yes, DSM-Firmenich is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of DSM-Firmenich?DSM-Firmenich's last 12 months EBITDA is $2B.
What is DSM-Firmenich's EBITDA margin?DSM-Firmenich's last 12 months EBITDA margin is 19%.
What is the current EV/EBITDA multiple of DSM-Firmenich?Current EBITDA multiple of DSM-Firmenich is 9.3x.
What is the current FCF of DSM-Firmenich?DSM-Firmenich's last 12 months FCF is $871M.
What is DSM-Firmenich's FCF margin?DSM-Firmenich's last 12 months FCF margin is 7%.
What is the current EV/FCF multiple of DSM-Firmenich?Current FCF multiple of DSM-Firmenich is 26.5x.
How many companies DSM-Firmenich has acquired to date?As of May 2026, DSM-Firmenich has acquired 2 companies.
What was the largest acquisition by DSM-Firmenich?$297M acquisition of Adare Biome on 19th April 2023 was the largest M&A DSM-Firmenich has done to date.
What companies DSM-Firmenich acquired?DSM-Firmenich acquired Adare Biome and DSM.
In how many companies DSM-Firmenich has invested to date?As of May 2026, DSM-Firmenich has invested in 1 company.
What was the last DSM-Firmenich investment?On 13th March 2024 DSM-Firmenich invested in Cynomys, participating in a $2M Seed round, alongside Farming Future, Levante Capital, PLUS9, and SVG Ventures.
In what companies DSM-Firmenich invested in?DSM-Firmenich invested in Cynomys.

See public comps similar to DSM-Firmenich

Lists including DSM-Firmenich

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial